New draft guidance from the Food and Drug Administration covers deciding whether and how to use EHRs as a data source in clinical trials.

While the new guidance provides general guidance on EHR capabilities, the new draft does not include provisions under which the FDA would assess compliance of records systems.

Register or login for access to this item and much more

All Information Management content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access